| 000 | 01562 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515162154.0 | ||
| 264 | 0 | _c20090311 | |
| 008 | 200903s 0 0 eng d | ||
| 022 | _a1533-4406 | ||
| 024 | 7 |
_a10.1056/NEJMc0808282 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYong, Patrick F K | |
| 245 | 0 | 0 |
_aRituximab and omalizumab in severe, refractory insulin allergy. _h[electronic resource] |
| 260 |
_bThe New England journal of medicine _cMar 2009 |
||
| 300 |
_a1045-7 p. _bdigital |
||
| 500 | _aPublication Type: Letter | ||
| 650 | 0 | 4 |
_aAnti-Allergic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Anti-Idiotypic |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 1 _xdrug therapy |
| 650 | 0 | 4 |
_aDrug Eruptions _xdrug therapy |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin E _xblood |
| 650 | 0 | 4 |
_aImmunologic Factors _xtherapeutic use |
| 650 | 0 | 4 |
_aInsulin _xadverse effects |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aOmalizumab |
| 650 | 0 | 4 | _aRituximab |
| 700 | 1 | _aMalik, Rifat | |
| 700 | 1 | _aArif, Sefina | |
| 700 | 1 | _aPeakman, Mark | |
| 700 | 1 | _aAmiel, Stephanie | |
| 700 | 1 | _aIbrahim, Mohammad A A | |
| 700 | 1 | _aGough, Andrew | |
| 773 | 0 |
_tThe New England journal of medicine _gvol. 360 _gno. 10 _gp. 1045-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1056/NEJMc0808282 _zAvailable from publisher's website |
| 999 |
_c18705161 _d18705161 |
||